Please try another search
For the fiscal year ended 31 December 2019, Ra Pharmaceuticals Inc revenues increased 20% to $3M. Net loss increased 58% to $102.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research & Development - Balancing value increase of 49% to $74.8M (expense), General & administrative - Balancing val increase of 95% to $21.2M (expense).
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Total Revenue | 0 | 3 | 0 | 0 |
Gross Profit | ||||
Operating Income | -37.83 | -26.22 | -22.85 | -20.09 |
Net Income | -36.78 | -24.98 | -21.9 | -19.04 |
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Total Assets | 284.15 | 308.94 | 189.24 | 205.07 |
Total Liabilities | 22.04 | 15.18 | 15.55 | 13.81 |
Total Equity | 262.11 | 293.76 | 173.69 | 191.25 |
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -87.36 | -58.75 | -36.39 | -18.02 |
Cash From Investing Activities | -0.86 | -0.63 | -0.42 | -0.2 |
Cash From Financing Activities | 143.4 | 142.16 | 0.59 | 0.04 |
Net Change in Cash | 55.17 | 82.78 | -36.22 | -18.18 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review